Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Octreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

pembrolizumab 40 Carboplatin 35 Cisplatin 31 Paclitaxel 25 Nivolumab 22 Pemetrexed 21 Gemcitabine 20 Dexamethasone 19 Ipilimumab 16 Rituximab 16 Cyclophosphamide 14 Fluorouracil 12 Lenalidomide 12 Docetaxel 11 atezolizumab 11 Bevacizumab 10 Capecitabine 10 Cytarabine 10 Prednisone 10 daratumumab 10 durvalumab 10 trastuzumab deruxtecan 10 Bortezomib 9 olaparib 9 130-nm albumin-bound paclitaxel 8 Leucovorin 8 Trastuzumab 8 Crizotinib 7 Daunorubicin 7 Doxorubicin 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡